Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Ulrich-Merzenich (Bonn, Germany), A. Tüschen (Bonn, Germany), T. Schaarschmidt (Bonn, Germany), A. Shcherbakova (Bonn, Germany), I. Tuleta (Bonn, Germany), U. Juergens (Bonn, Germany). CD4cell profiling to support endotypical stratification of severe allergic asthma - an update. 4389

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - The blood eosinophils count as a predictor of the response for omalizumab (OMA) in patients suffering from severe allergic asthma Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019 Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study. Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Two novel, severe asthma phenotypes identified during childhood using a clustering approach Source: Eur Respir J 2012; 40: 55-60 Year: 2012 Immunotherapy in severe asthma Source: ERS webinar 2021: Immunotherapy in severe asthma Year: 2021 Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005 Management of difficult-to-treat severe asthma Source: Eur Respir Mon 2011; 51: 282-296 Year: 2011 Refining asthma treatment for mild asthma Source: Virtual Congress 2020 – Rethinking asthma Year: 2020 Ykl-40 and phenotyping of severe asthma Source: International Congress 2019 – Immunopathological mechanisms of lung disease Year: 2019 Anti-IgE treatment, airway inflammation and remodelling in severe allergic asthma: current knowledge and future perspectives Source: Eur Respir Rev 2015; 24: 594-601 Year: 2015 Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma Source: ERJ Open Res, 7 (2) 00528-2020; 10.1183/23120541.00528-2020 Year: 2021 ‘Real-life‘ persistence beyond the first year of omalizumab treatment in patients with severe allergic asthma: The R-Pixel study Source: Annual Congress 2011 - Asthma management and response Year: 2011 Defining the clinical clusters of severe asthma within UBIOPRED Source: International Congress 2015 – Fingerprinting severe asthma Year: 2015 Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007 The ERS/EAACI statement on severe exacerbations of asthma, and how to deal with non-allergic severe asthma Source: International Congress 2019 – Pathophysiology and clinical insights into severe non-allergic asthma Year: 2019 A novel evaluation of the impact of severe allergic asthma in children: The family perspective Source: Annual Congress 2010 - Quality of life, asthma control and monitoring childhood asthma Year: 2010 Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021 The evaluation and biomarkers of severe asthma Source: Annual Congress 2010 - Severe asthma: reviewing the last decade and looking to the next. A report of the ERS/ATS Task Force Year: 2010 Inflammatory biomarkers in the evaluation of two-year  outcomes  of omalizumab treatment in severe allergic asthma. Source: International Congress 2018 – Biomarkers for evaluating asthma Year: 2018 Evaluation and management of difficult-to-control asthma Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007 The link between fungi and severe asthma: a summary of the evidence Source: Eur Respir J 2006; 27: 615-626 Year: 2006